WO2004000313A3 - Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 - Google Patents
Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 Download PDFInfo
- Publication number
- WO2004000313A3 WO2004000313A3 PCT/FR2003/001924 FR0301924W WO2004000313A3 WO 2004000313 A3 WO2004000313 A3 WO 2004000313A3 FR 0301924 W FR0301924 W FR 0301924W WO 2004000313 A3 WO2004000313 A3 WO 2004000313A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- pgc
- activity
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003260618A AU2003260618A1 (en) | 2002-06-24 | 2003-06-23 | Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0207783A FR2841141A1 (fr) | 2002-06-24 | 2002-06-24 | Nouvelles approches therapeutiques de la sclerose lateral amyotrophique |
FR02/07783 | 2002-06-24 | ||
US39326102P | 2002-07-02 | 2002-07-02 | |
US60/393,261 | 2002-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004000313A2 WO2004000313A2 (fr) | 2003-12-31 |
WO2004000313A3 true WO2004000313A3 (fr) | 2004-04-22 |
Family
ID=30001929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/001924 WO2004000313A2 (fr) | 2002-06-24 | 2003-06-23 | Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003260618A1 (fr) |
WO (1) | WO2004000313A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2579093A1 (fr) * | 2004-09-03 | 2006-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions et procedes de modulation de pgc-1.alpha. pour le traitement de maladies et de troubles neurologiques |
WO2011074690A1 (fr) * | 2009-12-14 | 2011-06-23 | Kyoto University | Composition pharmaceutique destinée à la prévention ou au traitement de la sclérose latérale amyotrophique |
DK2844256T3 (da) | 2012-05-02 | 2023-03-27 | Univ Georgetown | Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer |
CN113384569A (zh) * | 2013-09-18 | 2021-09-14 | 乔治城大学 | 用非诺贝特及其类似物治疗神经退行性疾病 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058473A2 (fr) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx» |
WO2001035096A2 (fr) * | 1999-11-10 | 2001-05-17 | Mitokor | Modulation de la masse et de la fonction mitochondriales permettant de traiter des maladies, et de cibler et de decouvrir des medicaments |
-
2003
- 2003-06-23 WO PCT/FR2003/001924 patent/WO2004000313A2/fr not_active Application Discontinuation
- 2003-06-23 AU AU2003260618A patent/AU2003260618A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058473A2 (fr) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx» |
WO2001035096A2 (fr) * | 1999-11-10 | 2001-05-17 | Mitokor | Modulation de la masse et de la fonction mitochondriales permettant de traiter des maladies, et de cibler et de decouvrir des medicaments |
Also Published As
Publication number | Publication date |
---|---|
AU2003260618A1 (en) | 2004-01-06 |
WO2004000313A2 (fr) | 2003-12-31 |
AU2003260618A8 (en) | 2004-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005004802A3 (fr) | Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer | |
WO2005032471A3 (fr) | Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer | |
WO2005004803A3 (fr) | Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer | |
EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
WO2004062625A3 (fr) | Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer | |
IL173348A (en) | Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs | |
WO2003016475A3 (fr) | Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur | |
WO2008063382A3 (fr) | Antagonistes de pcsk9 | |
WO2008057458A3 (fr) | Antagonistes de pcsk9 | |
WO2008133647A3 (fr) | Antagonistes de pcsk9 | |
WO2004047760A3 (fr) | Nouveaux composes chimiques | |
DE50206657D1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
AU2003221745A1 (en) | rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES | |
TR200500221T2 (tr) | Farmasötik Maddeler Olarak Bisiklik Amino Asitler | |
AU2002349352A1 (en) | Keratinocytes which may be used as biologically active substances for the treatment of wounds | |
WO2005018545A3 (fr) | Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer | |
WO2007025988A3 (fr) | Formulations liquides d'hormone de croissance pegylee | |
WO2006078576A3 (fr) | Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer | |
WO2007058862A3 (fr) | Composes d’imidazolidinone utiles en tant qu’inhibiteurs de la beta-secretase lors du traitement de la maladie d’alzheimer | |
WO2003016563A3 (fr) | Cible moleculaire de la neurotoxicite | |
WO2001079164A3 (fr) | Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques | |
WO2003010291A3 (fr) | Traitement de troubles concernant les cellules immunitaires et les cellules b | |
WO2006017355A3 (fr) | Variants d'aprotinine ameliores | |
IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |